From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
November 30, 2023
Philadelphia, PA, November 13, 2023 – IntegriChain, delivering pharma’s only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that its Gross-to-Net (GTN) experts will present at Informa’s upcoming Pharma | Biotech GTN Summit. Jen Sharpe, Vice President of Gross-to-Net Operational Consulting and facilitator of the Revenue Analytics Collaborative, and Jeff Baab, Vice President of Operational Consulting, have extensive experience in GTN automation, advising Pharma manufacturers of all sizes, business stages, and complexity on SaaS and BPaaS solutions for GTN forecasting, accruals, and analytics. Jen Sharpe is Chairperson and IntegriChain is a sponsor of the conference, which runs November 13 to 15 in Philadelphia.
Details of IntegriChain’s sessions during the conference are as follows.
Monday, November 13Revenue Analytics Collaborative Hot Topics4:30 – 5:30 pmJen Sharpe, Moderator
This interactive roundtable session is hosted by the Revenue Analytics Collaborative, IntegriChain, and various participating sponsors.
Tuesday, November 14Keynote: Navigating the Evolving Regulatory and Financial Landscape — Key Considerations and Recommendations for IRA, the AMP Cap Removal and Future Drug Policy Proposals8:45 – 9:45 am
Jeff Baab, ModeratorAnthony Fiordaliso, Vice President, US Commercial Contracts & Pricing, AbbvieChris Sloan, Director, Market Access Strategy, Blueprint MedicinesSean Dickson, Senior Vice President, Pharmaceutical Policy and Strategy, America’s Health Insurance PlansChris Schott, Partner, Latham & Watkins
This session explores the latest developments for the IRA, CMS, and AMP cap removal and their implications; discusses top tips and pitfalls to avoid when ensuring regulatory financial compliance and planning; and maps the political and legislative landscape and what’s on the horizon.
Technological advancements in GTN management: From automation to AI, leveraging innovation for effective GTN optimization9:45 – 10:45 am
Jen Sharpe, ModeratorFrank Panaro, Director, Corporate Finance, Sunovion PharmaceuticalsEkaterina Miteiko, Associate Director, Financial Planning & Analytics, Operations & Strategy, Mitsubishi Tanabe Pharma America, Inc.Kary Callahan, Director, Finance, Paratek PharmaceuticalsRochelle Cupelli, VP, Finance, Ironshore PharmaceuticalsMelissa Nortom, Assistant Controller, Revenue, TolmarGeorge Kappus, Associate Director, M&S Controlling (GtN), Boehringer Ingelheim
This session explores how to assess a company’s GTN needs, including the use of automation, cloud, and software in supporting GTN. It will explore the pros and cons of in-house and outsourced solutions, as well as the impact of AI have on analytics and forecasting. In addition, the session will discuss how manufacturers can have capable processes, cross-functional collaboration, and talent in place to support technology implementation.
IRA Impacts on GTN: Changing Policy and Drug Pricing ProposalsJeff Baab11:25 am – 12:25 pmThis session will tap into Baab’s extensive expertise on the impact of the Inflation Reduction Act on drug pricing and GTN.
About IntegriChain’s Gross-to-Net Solutions and Operational Consulting ProgramsIntegriChain offers a full suite of Gross-to-Net Solutions and Operational Consulting programs, including:
GTN Accrual Management. An end-to-end solution for Market Access and Finance departments, pre-configured for all standard line items with robust out-of-the-box accrual methodologies, including inventory and pipeline adjustments to accruals, balance sheet reconciliation to ERP systems, and true-up functionality.
GTN Accrual Forecasting. Based on industry-standard forecast methodologies configured for each liability line item with the ability to execute multiple scenario analyses for forecasts along with functionality to compare scenarios to improve forecast accuracy, GTN modeling, and financial close efficiency.
GTN Analytics. Delivering visibility to comprehensive market access datasets that power the accuracy of GTN accruals and forecasting processes, best practices GTN reports and metrics, and visualizations of GTN trends that allow for better accrual and net-price predictability and decision-making.
GTN Operational Consulting. IntegriChain industry experts routinely advise manufacturers on GTN readiness for launch, GTN process assessments, and GTN market analysis.
About the Revenue Analytics CollaborativeThe RAC comprises more than 800 Life Sciences business and financial professionals who own, support and analyze Commercial, Government, GTN, and Trade/Channel data, processes and systems in Pricing & Contracting, Pre-Deal Analytics & Performance Monitoring, Rebate & Chargeback Management & Adjudication; Government Pricing Reporting & Analytics, GTN Channel Forecasting & Scenario Modeling; GTN Accrual & Balance Sheet Management, Report, and Analytics, as well as Trade & Channel. The collaborative facilitates timely and relevant knowledge sharing via anonymous Collab forums, benchmarking, colleague connect for networking, lunch & learns, webinars, and the annual RAC Summit. For details or to join, visit racollab.org.
About IntegriChainAbout IntegriChainIntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma’s only data-driven commercialization platform — from strategy to operational execution. The Company’s unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte Platform, IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm, and is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit www.integrichain.com or follow on LinkedIn.
ContactJennifer Guinan, Sage Strategic Marketing, 610.410.8111, Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
